Report Overview
Omeprazole API (Active Pharmaceutical Ingredient) is a crucial component in the production of omeprazolebased medications, which are widely used to treat acidrelated disorders such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.
Omeprazole belongs to the proton pump inhibitor (PPI) class, reducing stomach acid production and providing relief from acid reflux symptoms. The API is formulated into various dosage forms, including tablets, capsules, and suspensions, catering to diverse patient needs.
Market Analysis
The global Omeprazole API Market was valued at US$ 185.7 million in 2024 and is expected to reach US$ 387.4 million by 2032, exhibiting a CAGR of 9.6% during the forecast period (2024-2032).
The market has witnessed steady growth due to the increasing prevalence of gastrointestinal disorders, rising geriatric population, and growing demand for cost-effective medications.
Historical data from 2018-2023 indicates a consistent demand trajectory, reflecting the pharmaceutical sector's reliance on omeprazolebased treatments.
